New leadership at Seattle-area companies including Starbucks, Avanade, Tune Therapeutics, Umoja Biopharma, Siteimprove and ...

Sage Therapeutics CEO Barry Greene expressed his gratitude for her contributions, particularly highlighting her advocacy for maternal mental health. Mike Quirk, the current Chief Scientific ...

Despite challenging market conditions, the stock has shown resilience with a 32.6% year-to-date return. Sage Therapeutics CEO Barry Greene expressed his gratitude for her contributions, particularly ...

Dube, CEO of Travere Therapeutics, Inc. (NASDAQ ... reflecting the firm's continued expectation for the peak revenue of SAGE, a product in Travere's pipeline. Analyst Ed Nash noted the challenges ...

Sage Therapeutics has said it will cut its headcount ... to launch Zurzuvae and help women suffering with PPD," said Sage's CEO, Barry Greene . "Executing on launch and our potential long ...

Scotiabank analyst George Farmer maintained a Hold rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

Codoxo, the leading provider of artificial intelligence solutions in payment integrity and cost containment for healthcare payers, government agencies and pharmacy benefit managers, today announced a ...

Biogen's strategic missteps, including the failed Sage Therapeutics acquisition ... Amidst all of this debacle, Biogen's CEO Christopher A. Viehbacher received $30.5m in pay and stock option ...

Sage Therapeutics, the Massachusetts-based company that makes ... Dr. Rashad Ali, an OB and the CEO of the clinic who has ...

Baxter cites several examples in which UC Davis is succeeding in translating research into solutions. Sage Therapeutics, based in Cambridge, Mass., licensed UC Davis technology to develop the only FDA ...